Market Size of Hypogonadism Treatment Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 3.00 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hypogonadism Treatment Market Analysis
The Hypogonadism Treatment Market is expected to register a CAGR of 3% during the forecast period attributing to increase in the incidence of hypogonadism, a rise in awareness about the disease and its treatment options and growth of infertility rate. Moreover, high risk of hypogonadism in the geriatric population and patient pool with diabetes and obesity are also some of the key drivers in the hypogonadism treatment market. For instance, according to a report published by the National Institute of Health (NIH), in 2019 obesity is increasing worldwide and the prevalence of hypogonadism is significantly greater in males with obesity. In addition, men aged between 60-80 years have low testosterone levels by 20% and 80% than normal testosterone levels in young men. Men above 60 years have the highest prevalence of hypogonadism. Thus, countries surging the geriatric population are witnessing a high demand for therapies to treat hypogonadism, hence, driving the hypogonadism market.